Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 13/20 | 0.71 |
| ▸ | CCNB2 | O95067 | 11/20 | 0.71 |
| ▸ | CCNB3 | Q8WWL7 | 11/20 | 0.71 |
| ▸ | CDK2 | P24941 | 5/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.53 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | CCNH | P51946 | 1/20 | 0.52 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137281 | 0.89 | CDK1 (0.57) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL21943153 | 0.89 | CDK1 (0.61) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL18521194 | 0.87 | CCNB2 (0.82) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL26354839 | 0.84 | CDK1 (0.72) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL26354422 | 0.82 | CDK1 (0.69) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL16707340 | 0.82 | CDK1 (0.67) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL18520056 | 0.81 | YTHDC1 (0.61) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL756298 | 0.79 | YTHDC1 (0.62) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL22326729 | 0.78 | ADORA2A (0.66) | CDK1CCNB1CCNB2CCNB3HTT | |
| SCHEMBL18520987 | 0.78 | HTT (0.58) | CDK1CCNB1CCNB2CCNB3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| WO-2020117625-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117624-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117623-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | US | disclosed |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2018118664-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018118665-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | CDK1 3267/4885CCNB1 4583/4885CCNB2 4689/4885 |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | CDK1 4739/4885CCNB1 4816/4885CCNB2 4833/4885 |
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | CDK1 1484/4885CCNB1 2785/4885CCNB2 2890/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | CDK1 4739/4885CCNB1 4816/4885CCNB2 4833/4885 |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | CDK1 2009/4885CCNB1 4422/4885CCNB2 4521/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | CDK1 1642/4885CCNB1 2975/4885CCNB2 2974/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | CDK1 2787/4885CCNB1 3587/4885CCNB2 3315/4885 |
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | CDK1 1465/4885CCNB1 2798/4885CCNB2 2879/4885 |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | CDK1 4386/4885CCNB1 4738/4885CCNB2 4657/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | CDK1 1503/4885CCNB1 3518/4885CCNB2 3381/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | CDK1 1548/4885CCNB1 2850/4885CCNB2 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.